The aim of the study was to determine the effectiveness of 2-chlorodeoxyadenosine (2-CdA) administered in 2-h i.v. infusions in the treatment of B cell chronic lymphocytic leukemia (B-CLL) in patients 55 years old and younger. One hundred and thirteen patients received three to 10 courses of 2-CdA administered at a dose of 0.12 mg/kg daily for 5 consecutive days. Sixty-seven patients were previously treated with chlorambucil and prednisone, COP and some of them also with CHOP, and 46 were untreated. Complete remission (CR) was achieved in 21 (18.6%) (19 in untreated and two in previously treated) patients and partial response (PR) in 38 (33.6%) (23 and 15, respectively) giving an overall response rate in 52.2%. The differences in CR and overall response rate between previously treated and untreated patients were statistically significant (P = 0.001). Surface immunophenotyping by flow cytometry using dual-color staining on the peripheral blood and/or bone marrow was performed in 38 patients who responded to 2-CdA therapy. Residual disease had been demonstrated in five out of 17 (29.4%) patients who were in CR and in all 21 investigated PR patients. 2-CdA-induced thrombocytopenia occurred in 24 (35.8%) of previously treated and in 13 (28.3%) previously untreated patients (P = NS). Neutropenia was observed in eight (11.9%) and in five (10.9%) patients, respectively (P = NS). Severe infections, including pneumonia and sepsis, occurred more often in previously treated (44.8%) than untreated patients (26.1%) (P Ͻ 0.05). Twenty-seven (23.9%) patients died, 11 because of infections, five because of drug-related thrombocytopenia and hemorrhage, one because of second malignancy and eight because of disease progression. In conclusion, our results indicate that 2-CdA is an effective agent in younger patients with B-CLL, especially used as a first line therapy.
Introduction
B cell chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries. CLL is generally perceived as an indolent, but incurable disease predominantly affecting elderly people. The median age of patients at diagnosis is 65 years, with only 10-15% of them being less than 55 years of age. 1, 2 Cases below the age of 40 are extremely rare. 3 The disease is characterized by a variable course with overall survival ranging from less than 1 year to more than 25 years. 4 Older age has been consistently shown to confer a poorer prognosis in CLL. [5] [6] [7] However, when non-CLL mortality is eliminated from an older population, there is no difference in median survival time between the patients younger than the age of 50 and the older group. 8 CLL is currently an incurable disease when using conventional chemotherapy such as alkylating agents, combined chemotherapy and even newer purine analogues. 9, 10 For patients younger than 50 years, the diagnosis of early stage Correspondence: T Robak, Department of Hematology, Medical University of Łó dź, 93-513 Łó dź, ul. Pabianicka 62, Poland; Fax: 4842 6846890 Received 6 October 1998; accepted 15 December 1998 CLL shortens expected survival by an average of 19 years. 11 Thus, in particular for younger patients, new treatment modalities that have the potential to provide long-term remissions or to completely eradicate the disease are required.
Newer nucleoside analogues, especially fludarabine (FAMP) and 2-chlorodeoxyadenosine (2-CdA), are highly active against CLL. [12] [13] [14] Complete response rate (CR) induced with these agents is significantly higher than in patients treated with conventional chemotherapy. 15, 16 High quality of response to first-line therapy is especially important in selected younger patients with CLL, who might be candidates for stem cell transplantation.
Here, we report the efficacy and toxicity of 2-CdA given in 2-h infusions as a first-line therapy in 115 patients with CLL, aged 55 years and younger.
Patients and methods

Patients
Between September 1994 and August 1998, 113 patients aged 55 years or less with progressive or symptomatic B-CLL were treated with 2-CdA. The characteristics of the patients are shown in Table 1 . All the patients fulfilled the National Cancer Institute-Sponsored Working Group diagnostic criteria for CLL. 17 They had peripheral lymphocytosis greater than 10 × 10 9 /l and more than 30% lymphocytes in a normal to hypercellular bone marrow. Immunologically all patients were CD5, CD19, CD20 and CD23 positive and showed monoclonality for light chain immunoglobulin membrane surface receptors. Pretreatment evaluation included medical history, physical examination, complete blood cell count, differentiation analysis, chemical survey, bone marrow examination and serum immunoglobulin level quantitation.
The clinical stage of disease was determined at the time of initiation of 2-CdA treatment according to Rai's classification. 18 The distribution is shown in Table 1 . Fifty-two patients with Rai stage III or IV were included in the study. Patients with stage 0, I and II were eligible if they had evidence of active disease, including progressive lymphocytosis, massive splenomegaly or bulky lymphadenopathy, recurrent disease-related infections, weight loss у10% over a 6-month period, fever of above 38°C related to disease or extreme fatigue. At the start of therapy they had normal renal (creatinine Ͻ1.0 mg/dl) and hepatic (bilirubin Ͻ1.0 mg/dl) functions and were free of active infections. Sixty-seven patients had been previously treated with chlorambucil and prednisone followed by polychemotherapy according to COP and/or CHOP schedules (49 patients) when they relapsed or were refractory to an alkylating agent. Forty-six patients were newly diagnosed or previously untreated and given 2-CdA because of progressive disease.
The study was approved by the Local Ethical Committees and the patients had signed the consent form. 19 More recently it was commercially available from the Institute of Biotechnology and Antibiotics (Warsaw). Treatment course consisted of 2-CdA at a dose of 0.12 mg/kg/24 h in a 2-h infusion for 5 consecutive days. In patients in whom 2-CdA induced hematological complications (thrombocytopenia Ͻ50 × 10 9 /l and/or neutropenia Ͻ1 × 10 9 /l) or severe infections developed, the drug was readministered at time intervals longer than 1 month, ranging from 2 to 3 months, until the hematological parameters increased or infections were resolved. If a complete response was achieved, no further 2-CdA treatment was administered.
Packed red blood cells were transfused for symptomatic anemia or prophylactically if the hemoglobin level was lower than 7.0 g/dl. Platelets were administered prophylactically if the platelet count was less than 15.0 × 10 9 /l. In order to prevent hyperuricemia, allopurinol (300 mg daily) was routinely given. No patients received antibiotics prophylactically. In the patients in whom 2-CdA induced autoimmune hemolytic anemia (AIHA) or progressive thrombocytopenia developed, prednisone at a initial dose of 0.5-1.0 mg/kg/24 h was introduced.
Response criteria
Physical examination and peripheral blood analysis were performed before and after every 2-CdA course, and the response to the drug was estimated. Bone marrow biopsy and immunophenotypic studies were performed to confirm complete remission, after every 2-3 courses of 2-CdA. Guidelines for response were those developed by the NCI-Sponsored Working Group. 17 Complete response (CR) required the absence of symptoms and organomegaly, a normal complete blood cell count (absolute neutrophil count Ͼ1 × 10 9 /l, hemoglobin con-
/l) and bone marrow with less than 30% of lymphocytes for at least 2 months. Partial response (PR) was considered as 50% or greater decrease in the size of lymph nodes, liver and spleen, and peripheral blood findings either identical to those of CR or improved over pre-therapy values by at least 50%. No bone marrow evaluation was required for determination of PR. The patients who had not achieved CR or PR were classified as non-responders (NR). Clinical relapse was defined according to Robertson et al 12 as increase in the absolute lymphocyte count above 10 × 10 9 /l, more than 50% increase in the sum of the sizes of at least two lymph nodes, appearance of new lymph nodes, more than a 50% increase in the liver or spleen below the costal margin, new appearance of palpable hepatosplenomegaly or development of an aggressive lymphoma.
Toxicity monitoring
Hematological toxicity was evaluated according to criteria developed by the NCI-Sponsored Working Group. 17 2-CdAinduced anemia, thrombocytopenia and neutropenia were assessed if after the treatment course further decrease of hemoglobin level and/or platelets and neutrophils number was observed. Other toxic effects were monitored and assessed according to the standard criteria. 20 The blood counts, creatinine, bilirubin, GOT, GPT, ECG, urinalysis and general physical examination were serially evaluated and recorded.
Immunophenotype analysis
Immunophenotyping was performed on peripheral blood and bone marrow by flow cytometry using a simultaneous dualcolor staining technique, before treatment, after three and six courses of 2-CdA, and then after every 6 months. Blood was collected in vacuum tubes with EDTA as anticoagulant. Bone marrow cells were aspirated from the dorsal iliac crest and immediately put into heparinized tubes. 21 
Statistical analysis
The significance of differences was evaluated by Mann-Whitney U test at the level of confidence P Ͻ 0.05. Statistical analysis of the difference in percentages of patient responses was evaluated by the 2 test.
Results
The results of the treatment of 113 patients with B-CLL, 55 years old and younger using 2-CdA in a 2-h infusion, are summarized in CR and overall responses were achieved more frequently in the patients in whom 2-CdA was first-line treatment than in previously treated patients and the differences were statistically significant (P Ͻ 0.001, Table 2 ). The median duration of CR for previously untreated patients was 10.1 months (range 4-34) and for patients previously treated with one or more regimens 5.9 months (range 3-27) (P = 0.001). The CRs were observed after a median of three cycles (range 2-6) and after a median four (range 3-7), respectively. The influence of Rai stage before 2-CdA therapy on the response to the treatment is shown in Table 2 . CRs were achieved more frequently in the early stages of the disease (Rai 0, I and II), than in more advanced stages (Rai III and IV, P Ͻ 0.05). Treatment with 2-CdA was discontinued when response was observed. The median duration of response was 10.4 months, with a range of 2-34. Disease progression occurred in 54 patients, including 50 in the previously treated group and four in the untreated group. Eighteen patients are still in CR and 22 in PR. Surface immunophenotyping by flow cytometry using dualcolor staining on the peripheral blood and/or bone marrow was performed in 38 patients who responded to 2-CdA therapy. Residual disease was demonstrated in five out of 17 (29.4%) patients who were in CR and in all 21 investigated PR patients.
Toxicity of 2-CdA in the patients previously untreated as well as treated with conventional chemotherapy are presented in Table 3 . There was no significant difference between myelosuppressive effects of 2-CdA in both groups of patients. 2-CdA-induced thrombocytopenia occurred in 24 (35.8%) of previously treated and in 13 (28.3%) previously untreated patients (P Ͼ 0.05). The treatment with prednisone was introduced in 25 patients with thrombocytopenia and in 11 of them improvement was noticed. However, the percentage of autoimmune thrombocytopenia in this group is uncertain. Neutropenia was observed in eight (11.9%) of previously treated and in five (10.9%) untreated patients (P Ͼ 0.05). Severe infections, including pneumonia and sepsis, occurred more often in previously treated (44.8%) than untreated patients (26.1%) (P Ͻ 0.005).
2-CdA-related eosinophilia was observed in two patients. In one of them, marked eosinophilia (absolute eosinophil count Ͼ1.6 × 10 9 /l) followed allergic dermatitis, which occurred after two cycles of 2-CdA. Five patients experienced autoimmune hemolytic anemia (AIHA) after 2-CdA and one patient pure red cell aplasia (PRCA). AIHA was successfully treated with prednisone in four patients and one was refractory to such treatment. There were also simple episodes of non-hematologic toxic effects of 2-CdA in both groups. The observed side-effects comprised polyneuropathy in two patients, dermatitis in three patients, abnormal aminotransferases in three and increased LDH level in two patients. Increased creatinine level or overt renal insufficiency were found in two patients. In five patients skin manifestations were observed including erythema anulare, vasculitis allergica and 521 Table 4 . Infectious complications were the cause of death in 11 patients from the previously treated group. Seven patients died because of severe bilateral pneumonia, two in septic shock and two because of viral meningitis. Five patients died of hemorrhage, seven because of disease progression and one patient developed lung cancer.
Discussion
The therapeutic procedure in CLL is different and depends mainly on the clinical stage of disease and age of patients at diagnosis. The results of multicenter randomized trials indicate that therapy for indolent CLL using chlorambucil and prednisone does not prolong survival time. 22 However, the treatment of CLL should be undertaken in advanced stages of disease (stage B and C according to Binet's classification) or in progressive cases. The new purine analogs, fludarabine (FAMP) and 2-CdA, have been recently shown to be the most effective in CLL treatment, giving the highest response rate, particularly CR. 15, 16, 23 However, the main aim for purine analog administration in CLL, whose clinical course is usually chronic and often indolent, has not yet been precisely defined. The significance of the new purine analogs is particularly important for younger patients in whom achieving a CR may Table 4 Causes of death in B-CLL patients treated with 2-CdA
Cause of death Total Previously Previously n = 27 untreated treated n = 5 n= 22 Pneumonia  7  -7  Septic shock  2  -2  Meningitis  2  -2  Hemorrhage  5  2  3  Disease progression  8  1  7  Second malignancy  1  1  0 be crucial for prolongation of survival time and an increase in the efficacy of the bone marrow transplantation procedure. The present study estimates the efficacy of 2-CdA therapy in 113 B-CLL patients aged up to 55 years. The drug was given in a 2-h infusion for 5 consecutive days. The whole group consisted of 46 untreated and 67 patients, who became progressively or were resistant to previous therapy with chlorambucil, COP or CHOP. The highest overall response (91.3%) and CR (41.3%) rates were noted in previously untreated B-CLL patients in comparison to those who received 2-CdA as a second-or third-line therapy (overall response rate 25.4%, CR rate 3.0%). These differences were statistically significant (P Ͻ 0.001). In our previous study similar results were obtained in older B-CLL patients, who were given 2-CdA in a 2-h infusion achieving a CR in 16% of untreated vs 5.4% in previously treated patients. 13 Keating et al 24, 25 did not observe any difference in the response to FAMP among untreated or previously treated CLL patients aged Ͼ60 years. It should be noted, however, that retrospective analysis of 374 CLL patients treated with FAMP revealed that older age was an unfavorable prognostic factor in pretreated as well as in untreated patients. 26 It should be emphasized that in our study 2-CdA was administered in a 2-h infusion for 5 days and using this protocol we obtained the results comparable to those published earlier in CLL patients receiving both 2-h infusion and a continuous 24-h infusion for 7 days. [27] [28] [29] The efficacy of 2-CdA given as a 2-h vs a 24-h infusion was essentially the same also in hairy cell leukemia. 30 Pharmacokinetics studies confirm the effectiveness of 2-CdA given as 2-h bolus for shorter periods of time, ie for 5 instead of 7 days. 31, 32 Taking into account that a 2-h infusion is more convenient and may be given on an out-patient basis, our results seem to be important from a practical point of view.
The most dangerous and frequent 2-CdA related side-effect was thrombocytopenia which was noted in 32.7% of CLL patients, and in five of them the hemorrhagic complications were a cause of death. It should be noted, however, that we did not observe the difference in frequency of thrombocytopenia in untreated vs pretreated younger B-CLL patients. Nevertheless, in older CLL patients 2-CdA-induced profound thrombocytopenia was noted more frequently in patients treated previously with chlorambucil or polychemothera-peutic regimens. 13 This may be explained by a higher bone marrow reserve and, therefore, a better tolerance of myelosuppressive drugs in younger patients.
In our series an autoimmune hemolytic anemia (AIHA) was noted in five and pure red cell aplasia (PRCA) in one patient. These immune complications subsided after 2-CdA withdrawal and steroid administration. AIHA was observed in CLL patients treated with 2-CdA and FAMP. 33, 34 However, it cannot be definitely established whether this immune phenomenon is drug-induced or appears spontaneously in the natural course of CLL.
Infections were another severe and undesirable 2-CdA sideeffect being a cause of death in 11 (9.7%) patients. All of them were previously treated with cytostatics. It is well known that infectious complications are frequent causes of death in CLL, despite which treatment schedule is used, and they result mainly from severe and profound dysfunction of humoral and cellular immunity observed in this malignancy. However, prolonged treatment with 2-CdA, which is a potent immunosuppressive agent, may deepen the immune deficiency in CLL patients as was noted after FAMP administration. 35 Our observations indicate that 2-CdA-related myelo-and immunosuppression occurs also in younger CLL patients, becoming an important therapeutic problem. Betticher et al 36 reported a lower frequency of infections after a reduction of 2-CdA dose from 0.7 mg/kg given intravenously to 0.5 mg/kg administered subcutaneously in low-grade non-Hodgkin's lymphoma patients. Interestingly, the efficacy of both schedules was similar, which indicates that a lower 2-CdA dose may be therapeutically successful being at the same time less toxic.
An alternative route for the reduction of myelosuppressive 2-CdA effect may be the administration of cytokine stimulating granulopoiesis (ie G-CSF) which decreased the frequency of infections and neutropenia in CLL patients treated with FAMP from 37% in a historical control group to 8%. 37 Until now, there were no studies on the efficacy of thrombopoietin or IL-11 in preventing purine analog-related thrombocytopenia.
The essential problem in younger patients treated with new purine analogs for lymphoid malignancies is the monitoring of minimal residual disease (MRD) in order to qualify them for bone marrow transplantation, thus offering a possibility for recovery. 38 Using monoclonal antibodies and FACS technique, we searched for MRD in 17 CLL patients who achieved a CR according to hematological criteria. Immunophenotype remission according to criteria proposed by Briugatelli et al 21 was noted in 12 out of 17 (70.6% CLL) patients treated with 2-CdA and nine of them still remain in CR. These results are consistent with observations made by Robertson et al 12 in CLL patients treated with FAMP, who reported a complete eradication of leukemic clone in 89% of patients in CR and only in 19% of patients in PR according to hematological criteria. Moreover, MRD was undetectable exclusively in cases showing only lymphadenopathy at diagnosis. Progression-free survival time in MRD-negative patients was longer than in patients with detectable MRD in bone marrow. 12 Similar observations were made in CLL patients, who entered a CR after chlorambucil, COP or CHOP treatment. 21, 39 All these data indicate that the chance for achieving a durable CR or even recovery using new purine analogs in younger CLL patients is low, so other therapeutic procedures should be searched for. It seems that the use of monoclonal antibodies, cytokines or bone marrow transplantation may give promising results, especially in patients with poor prognostic factors. 40, 41 In conclusion, our study indicates, that 2-CdA gives a high response rate in CLL patients aged 55 years or less. The efficacy of the drug is higher and the toxicity is lower if 2-CdA is administered as first-line therapy. Immunophenotyping studies show that the complete eradication of leukemic clone may be achieved in some CLL patients. However, their chance for recovery seems to be less probable.
